Differential effects of the proteasome inhibitor NPI-0052 against glioma cells

Translational Oncology

Volumn 3, Issue 1, 2010, Pages 50-55

  Vlashi, Erina ^a   Mattes, Malcom ^a   Lagadec, Chann ^a   Donna, Lorenza Della ^a   Phillips, Tiffany M ^a   Nikolay, Polin ^a   McBride, William H ^a   Pajon, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME INHIBITOR; PROTEIN P53; SALINOSPORAMIDE A; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENE MUTATION; GLIOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR GROWTH; XENOGRAFT;

EID: 77953474728     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09244     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
2. Goldberg AL (2003). Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899.
3. Spataro V, Norbury C, and Harris AL (1998). The ubiquitin-proteasome pathway in cancer. Br J Cancer 77, 448-455.
4. Miller J and Gordon C (2005). The regulation of proteasome degradation by multi-ubiquitin chain binding proteins. FEBS Lett 579, 3224-3230.
5. Pajonk F and McBride WH (2001). The proteasome in cancer biology and treatment. Radiat Res 156, 447-459.
6. Kane RC, Bross PF, Farrell AT, and Pazdur R (2003). Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513.
7. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, and Pazdur R (2007). Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13, 5291-5294.
8. Pedeboscq S, L'Azou B, Passagne I, De Giorgi F, Ichas F, Pometan JP, and Cambar J (2008). Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J Exp Ther Oncol 7, 99-111.
9. Labussiere M, Pinel S, Delfortrie S, Plenat F, and Chastagner P (2008). Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. Oncol Rep 20, 1283-1287.
10. Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, Andrews D, Curran WJ Jr, and Dicker AP (2008). Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 74, 433-439.
11. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, and Fenical W (2003). Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed Engl 42, 355-357.
12. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, Deyanat-Yazdi G, Mai B, Jensen PR, Fenical WF, et al. (2005). Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48, 3684-3687.
13. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, and McConkey D (2006). The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 5, 1836-1843.
14. Chauhan D, Hideshima T, and Anderson KC (2006). A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 95, 961-965.
15. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
16. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
17. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. (2005). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8, 407-419.
18. Pajonk F, van Ophoven A, Weissenberger C, and McBride WH (2005). The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 5, 76.
19. Pajonk F, Grumann T, and McBride WH (2006). The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinomacells after cyclic hypoxia/reoxygenation from ionizing radiation. Neoplasia 8, 1037-1041.
20. Pajonk F, Himmelsbach J, Riess K, Sommer A, and McBride WH (2002). The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62, 5230-5235.
21. Pajonk F, Pajonk K, and McBride WH (2000). Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47, 1025-1032.
22. Pervan M, Pajonk F, Sun J-R, Withers HR, and McBride WH (2001). Molecular pathways that modify tumor radiation response. Am J Clin Oncol 24, 481-485.
23. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, et al. (2008). Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 44, 1829-1834.
24. Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, and Kumar P (2009). Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 100, 1379-1384.
25. Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, and Gore L (2009). A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 27, 53-62.
26. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, and Koeffler HP (2005). Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24, 344-354.
27. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, and Sminia P (2007). Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69, 1246-1253.
28. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, and Holland EC (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235.
29. Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, and Hirao Y (2008). Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther 7, 1864-1870.
30. Park JK, Jung HY, Park SH, Kang SY, Yi MR, Um HD, and Hong SH (2008). Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 70, 1552-1560.
31. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, and Slotman BJ (2000). Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 47, 779-784.
32. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5, 309-317.
33. Mortenson MM, Schlieman MG, Virudachalam S, and Bold RJ (2004). Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54, 343-353.
34. Johannessen TC, Bjerkvig R, and Tysnes BB (2008). DNA repair and cancer stem-like cells - potential partners in glioma drug resistance? Cancer Treat Rev 34, 558-567.
35. 1 growth arrest in glioma cells. Cancer Res 58, 5002-5008.
36. Vlashi E, Kim K, Dealla Donna L, Donna LD, McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W, and Pajonk F (2009). In-vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101, 350-359.